Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P0CI25

UPID:
TRI49_HUMAN

ALTERNATIVE NAMES:
RING finger protein 18; Testis-specific RING-finger protein

ALTERNATIVE UPACC:
P0CI25; A0AVR7; A0AVR9; Q6DJV1; Q9NS80

BACKGROUND:
The Tripartite motif-containing protein 49, with aliases such as RING finger protein 18 and Testis-specific RING-finger protein, is encoded by the unique identifier P0CI25. This protein is part of a larger family that plays significant roles in regulating cellular mechanisms, including apoptosis, cell cycle progression, and gene expression. Its specific functions and interactions within the cell highlight its importance in maintaining cellular homeostasis.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Tripartite motif-containing protein 49 offers a promising avenue for the development of novel therapeutic interventions. Given its pivotal role in fundamental cellular processes, targeting this protein could lead to breakthroughs in treating conditions associated with cellular dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.